The management of heart failure in Sweden.
Heart failure is a major concern to health care providers in Sweden due to its increasing prevalence and the rising health care costs. Heart failure affects more than 160000 Swedes, approximately 2% of the population. The costs for the management of heart failure have been calculated to be approximately SEK 2.500 million (Euro 275 million) which is 2% of the total health care budget. Most heart failure patients are managed by primary care physicians but hospitalisation is common and heart failure is the most common cause for hospitalisation in patients over 65 years of age. National diagnostic and treatment guidelines are not completely adhered to. Echocardiography is performed in a little more than 30% of patients in primary care probably due to poor access. In hospitals echocardiography is more easily available and routinely used for diagnosis. Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers appear to be under prescribed. Nurse-led heart failure clinics are being widely established in an attempt to curtail costs and improve management.
Cline
C M J
CM
Department of Cardiology, Malmö University Hospital, Lund University, SE-205 02, Malmö, Sweden. charles.cline@medforsk.mas.lu.se
Boman
K
K
Holst
M
M
Erhardt
L R
LR
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000368:Aged; D017281:Cost of Illness; D019468:Disease Management; D004452:Echocardiography / Q000706:statistics & numerical data; D019983:Guideline Adherence; D017048:Health Care Costs; D019538:Health Care Surveys; D005102:Health Expenditures; D006333:Heart Failure / Q000191:economics* / Q000451:nursing / Q000628:therapy*; D006801:Humans; D010044:Outpatient Clinics, Hospital / Q000458:organization & administration; D007703:Peptidyl-Dipeptidase A / Q000008:administration & dosage; D013548:Sweden
D000319:Adrenergic beta-Antagonists; D007703:Peptidyl-Dipeptidase A